- Condition: Surgical Site Infection
Interventions: Drug: Povidone-Iodine; Drug: Saline
Sponsors: Attabib, Najmedden, M.D.; Attabib, Najmedden, M.D.
Recruiting - verified April 2012 - Conditions: Colles Fracture; Point of Care Ultrasound; Emergency Ultrasound
Intervention: Device: Point of care ultrasound
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified April 2012 - Condition: Cardiac Sarcoidosis
Intervention:
Sponsors: University of Ottawa Heart Institute; University of Ottawa Heart Institute; Ontario Ministry of Health and Long Term Care
Not yet recruiting - verified December 2011 - Condition: Hypotension
Intervention: Device: Ultrasound
Sponsors: Saint John Regional Hospital; Saint John Regional Hospital
Recruiting - verified March 2012 - Condition: Atherosclerosis
Intervention:
Sponsors: Canadian Atherosclerosis Imaging Network; Canadian Atherosclerosis Imaging Network; Canadian Institutes of Health Research (CIHR)
Recruiting - verified July 2011 - Condition: Melanoma
Interventions: Drug: rIL-21; Drug: Dacarbazine
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012 - Condition: Multiple Myeloma
Intervention: Drug: AT9283
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Conditions: Chronic Obstructive Pulmonary Disease; Nocturnal Desaturation
Interventions: Device: Concentrator; Device: Sham concentrator
Sponsors: Laval University; Laval University; Canadian Institutes of Health Research (CIHR)
Recruiting - verified February 2012 - Condition: Lung Cancer
Interventions: Drug: PF-00299804; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Opioid (morphine sulphate) in low dose
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada; Canadian Institutes of Health Research (CIHR); Nova Scotia Health Research Foundation; Atlantic Health Sciences Corporation
Active, not recruiting - verified December 2011 - Conditions: Anxiety Disorder; Cognitive/Functional Effects; Colorectal Cancer; Depression; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Behavioral: exercise intervention; Other: counseling intervention; Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: fatigue assessment and management; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Head and Neck Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified November 2011 - Condition: Hematoma
Interventions: Drug: low molecular weight heparin or unfractionated heparin; Drug: Warfarin or coumadin
Sponsors: University of Ottawa Heart Institute; University of Ottawa Heart Institute; Canadian Institutes of Health Research (CIHR)
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwestern Oncology Group (SWOG); Cancer and Leukemia Group B
Active, not recruiting - verified May 2012 - Conditions: Acute Coronary Syndrome; Myocardial Infarction; Smoking
Interventions: Drug: Bupropion HCl ER; Drug: Placebo
Sponsors: McGill University; Mark Eisenberg; Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Quebec
Completed - verified May 2008 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: brivanib alaninate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Procedure: quality-of-life assessment; Radiation: Radiation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; European Organization for Research and Treatment of Cancer - EORTC; Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified March 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Doxorubicin; Drug: Cytarabine; Drug: Methotrexate; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Methylprednisone; Drug: Hydrocortisone Sodium Succinate; Drug: Dexamethasone; Drug: 6-MP; Drug: PEG-Asparaginase; Drug: Imatinib; Drug: Etoposide; Procedure: Radiation Therapy; Drug: E. coli Asparaginase
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Children's Hospital Boston
Recruiting - verified August 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: cyclophosphamide; Drug: prednisone; Drug: vincristine sulfate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012 - Condition: Lung Cancer
Intervention: Radiation: 3-dimensional conformal radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Radiation: 3D-CRT APBI; Radiation: WBI
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Canadian Breast Cancer Research Alliance
Active, not recruiting - verified July 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; British Medical Research Council; Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting - verified February 2012 - Condition: Apnea of Prematurity
Intervention: Drug: Caffeine citrate injection
Sponsors: McMaster University; McMaster University; Canadian Institutes of Health Research (CIHR); National Health and Medical Research Council, Australia
Active, not recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Grupo Espanol de Investigacion del Cancer de Mama; UNICANCER
Active, not recruiting - verified August 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cisplatin; Drug: cytarabine; Drug: dexamethasone; Drug: gemcitabine hydrochloride; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: docetaxel; Drug: epirubicin hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: CHOP regimen
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified August 2011 - Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Biological: epoetin alfa; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - verified May 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone; Drug: thalidomide
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride
Sponsors: National Cancer Institute (NCI); AGO Study Group; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Active, not recruiting - verified June 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Condition: Sarcoma
Intervention: Drug: alvocidib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: melphalan; Drug: prednisone
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Hodgkin Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: vinblastine; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group
Completed - verified January 2012 - Condition: Ovarian Cancer
Intervention: Drug: ISIS 5132
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Lung Cancer
Interventions: Drug: marimastat; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012 - Condition: Endometrial Cancer
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified March 2012
 |
Join Clinical Trials by University in New Brunswick |
